Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
224
datasets available to search
ShareScore release 0.9.0
Dataset results
224 results for “Disease Biology”
Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions
ClinicalTrials.gov study NCT03073109. IPD Sharing: NO. Countries: 2. Publications: 2.
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade
ClinicalTrials.gov study NCT02605642. IPD Sharing: NO. Countries: 7. Publications: 1.
Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis
ClinicalTrials.gov study NCT05572567. IPD Sharing: NO. Countries: 1. Publications: 1.
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs
ClinicalTrials.gov study NCT01578850. IPD Sharing: Not stated. Countries: 19. Publications: 3.
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (
ClinicalTrials.gov study NCT02075541. IPD Sharing: Not stated. Countries: 2. Publications: 2.
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheu
ClinicalTrials.gov study NCT00891020. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
ClinicalTrials.gov study NCT01490450. IPD Sharing: Not stated. Countries: 13. Publications: 1.
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic
ClinicalTrials.gov study NCT03104374. IPD Sharing: YES. Countries: 19. Publications: 14.
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
ClinicalTrials.gov study NCT02873936. IPD Sharing: NO. Countries: 15. Publications: 7.
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
ClinicalTrials.gov study NCT01941095. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
ClinicalTrials.gov study NCT00002663. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Th
ClinicalTrials.gov study NCT02001987. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Clinical Dataset for the Paper 'Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis'
<p>This dataset accompanies the manuscript titled "Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis." It includes clinical data used for training and evaluating the machine learning models described in the paper. The dataset contains baseline clinical data of 154 RA patients who were treated with bDMARDs. The labels for remission, and effectiveness (remission and low disease activity) were applied after a 6-month follow-up based on EULAR criteria on DAS28ESR. The sustained effectiveness label indicates maintaining effectiveness within 6 months after initially achieving effectiveness.</p> <p><strong>Crossponder Authors:</strong></p> <ul> <li>Fatemeh Salehi (email: <a rel="noreferrer">fatemeh.salehihafshejni@fau.de</a>)</li> </ul>
Fig. 6 in Astragalus species: Phytochemistry, biological actions and molecular mechanisms underlying their potential neuroprotective effects on neurological diseases
Fig. 6. The antiapoptotic effect of saponins in neurological diseases. They activate the PI3K/Akt survival pathway, promote the phosphorylationdependent inactivation of Bad, which leads to a decrease in caspasedependent neuronal apoptosis. Also, they maintain mitochondria integrity through modulation of p38 and mitogen-activated protein kinase (MEK) signalling pathways, which reduces the cytochrome c release and inhibits caspasedependent apoptosis (Wu et al., 2015).
Fig. 1 in Astragalus species: Phytochemistry, biological actions and molecular mechanisms underlying their potential neuroprotective effects on neurological diseases
Fig. 1. Chemical structures of the major constituents of triterpenoid saponins identified in Astragalus radix extract (Chu et al., 2010).
Fig. 5 in Astragalus species: Phytochemistry, biological actions and molecular mechanisms underlying their potential neuroprotective effects on neurological diseases
Fig. 5. Pathways through which Astragalus polysaccharides (APS) mediates anti-inflammatory effect (Zheng et al., 2020).
Fig. 3 in Astragalus species: Phytochemistry, biological actions and molecular mechanisms underlying their potential neuroprotective effects on neurological diseases
Fig. 3. Astragalus membranaceus: (A) Aerial parts, (B) Roots, (C) Root extract (Cited at https://www.cambridge.org).
Fig. 3 in Isosteroidal alkaloids of Fritillaria taipaiensis and their implication to Alzheimer's disease: Isolation, structural elucidation and biological activity
Fig. 3. Key NOESY () correlations for compounds 1–4 [some hydrogens were removed for a clearer exhibition of their 3D structures].
Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas
ClinicalTrials.gov study NCT02686229. IPD Sharing: NO. Countries: 1. Publications: 1.
Clinical Efficacy and Long-term Outcomes of ALLOgraft Versus Stented Biological Prosthesis for Primary TRIcuspid Valve Disease (ALLOTRI)
ClinicalTrials.gov study NCT06591000. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.